At IMV, we are proud to partner with investigators through our clinical development program. This includes engaging investigators for our ongoing clinical trials as well as supporting investigator-initiated research. If you are an investigator and would like more information on participating in our company-sponsored clinical trials, please send us an email at [email protected]. We aim to respond to all requests within seven (7) days.
IMV Inc. is a clinical-stage immuno-oncology company dedicated to making immunotherapies more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV's proprietary drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system. Lead product candidate DPX-Survivac is currently being evaluated in several clinical trials in advanced ovarian cancer in combination with other innovative immunotherapy agents.
© 2018 IMV Inc. All rights reserved.
130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4
© 2018 IMV Inc. All rights reserved.